Table 4_Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lym

A 2026 retrospective analysis of 195 adult patients with relapsed/refractory large B-cell lymphoma, conducted by Rui Liu. The dataset compares survival outcomes for patients with and without TP53 mutations, stratified by treatment with CAR-T cell therapy or chemotherapy-based approaches. It includes metrics such as objective response rates and median overall survival.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between TP53-mutated and wild-type patient groups.
• Analyze the association between TP53 mutation types (missense vs. disruptive) and treatment response rates.
• Evaluate the differential impact of CAR-T therapy versus chemotherapy on objective response rates in a defined patient cohort.
• Investigate the relationship between TP53 protein domain mutations (DBD vs. non-DBD) and survival trends post-treatment.

Strengths

• Includes data from 195 patients with Next-Generation Sequencing (NGS) results, providing a genetic basis for analysis.
• Contains specific survival metrics, including median overall survival (12.13 vs. 2.20 months) and objective response rates (56.6% vs. 18.2%) for key patient subgroups.
• Stratifies patients into four groups based on TP53 mutation status and treatment modality (CAR-T vs. chemotherapy), enabling comparative analysis.

Limitations

• Row count is unknown, which may limit suitability assessment for certain statistical methods.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single retrospective study; findings may reflect specific cohort characteristics.

Provenance

Source

Rui Liu via figshare

Collection Method

Retrospective analysis of patient records and Next-Generation Sequencing data.

Freshness

Last updated 2026-06-03 06:06:56; freshness should be verified.